A recent study conducted by researchers at Banaras Hindu University (BHU) revealed that over 30% of individuals who received Bharat Biotech’s Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest (AESI) such as stroke and Guillain-Barre syndrome reported in one per cent of recipients.
